Which has better valuation & earnings, VCYT or TWST?

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 6.58 $66.35M $1.41 30.01 Twist Bioscience $376.57M 24.25 -$77.67M -$2.22 N/A

Does the media prefer VCYT or TWST?

In the previous week, Veracyte and Veracyte both had 10 articles in the media. Veracyte's average media sentiment score of 1.29 beat Twist Bioscience's score of 0.79 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, VCYT or EXEL?

Exelixis has higher revenue and earnings than Veracyte. Exelixis is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 6.58 $66.35M $1.41 30.01 Exelixis $2.32B 5.78 $782.57M $3.18 17.01

Is VCYT or EXEL more profitable?

Exelixis has a net margin of 35.33% compared to Veracyte's net margin of 20.37%. Exelixis' return on equity of 42.17% beat Veracyte's return on equity. Company Net Margins Return on Equity Return on Assets Veracyte 20.37% 9.26% 8.61% Exelixis 35.33% 42.17% 31.76%

Does the media refer more to VCYT or EXEL?

In the previous week, Exelixis had 6 more articles in the media than Veracyte. MarketBeat recorded 16 mentions for Exelixis and 10 mentions for Veracyte. Veracyte's average media sentiment score of 1.29 beat Exelixis' score of 1.18 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BMRN or VCYT?

In the previous week, BioMarin Pharmaceutical had 24 more articles in the media than Veracyte. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 10 mentions for Veracyte. Veracyte's average media sentiment score of 1.29 beat BioMarin Pharmaceutical's score of 0.73 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 13 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VCYT or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 5 more articles in the media than Veracyte. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 10 mentions for Veracyte. Veracyte's average media sentiment score of 1.29 beat Arrowhead Pharmaceuticals' score of 0.90 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VCYT or HALO?

In the previous week, Halozyme Therapeutics had 5 more articles in the media than Veracyte. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 10 mentions for Veracyte. Veracyte's average media sentiment score of 1.29 beat Halozyme Therapeutics' score of 1.04 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Veracyte (VCYT) Competitors

$42.31 +0.52 (+1.24%)

As of 08/21/2026 04:00 PM Eastern

Compare

VCYT vs. TWST, EXEL, BMRN, ARWR, and HALO

Should you buy Veracyte stock or one of its competitors? Veracyte's main competitors and comparable companies include Twist Bioscience (TWST), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Arrowhead Pharmaceuticals (ARWR), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Veracyte compare to Twist Bioscience?

Veracyte (NASDAQ:VCYT) and Twist Bioscience (NASDAQ:TWST) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	6.58	$66.35M	$1.41	30.01
Twist Bioscience	$376.57M	24.25	-$77.67M	-$2.22	N/A

Veracyte currently has a consensus target price of $54.33, suggesting a potential upside of 28.42%. Twist Bioscience has a consensus target price of $98.30, suggesting a potential downside of 32.48%. Given Veracyte's stronger consensus rating and higher possible upside, equities analysts plainly believe Veracyte is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Veracyte has a net margin of 20.37% compared to Twist Bioscience's net margin of -31.66%. Veracyte's return on equity of 9.26% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Twist Bioscience	-31.66%	-28.64%	-19.94%

Veracyte has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

In the previous week, Veracyte and Veracyte both had 10 articles in the media. Veracyte's average media sentiment score of 1.29 beat Twist Bioscience's score of 0.79 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Veracyte beats Twist Bioscience on 11 of the 14 factors compared between the two stocks.

How does Veracyte compare to Exelixis?

Veracyte (NASDAQ:VCYT) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

85.3% of Exelixis shares are owned by institutional investors. 1.6% of Veracyte shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Veracyte presently has a consensus price target of $54.33, suggesting a potential upside of 28.42%. Exelixis has a consensus price target of $50.07, suggesting a potential downside of 7.42%. Given Veracyte's stronger consensus rating and higher possible upside, analysts plainly believe Veracyte is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30

Exelixis has a net margin of 35.33% compared to Veracyte's net margin of 20.37%. Exelixis' return on equity of 42.17% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Exelixis	35.33%	42.17%	31.76%

In the previous week, Exelixis had 6 more articles in the media than Veracyte. MarketBeat recorded 16 mentions for Exelixis and 10 mentions for Veracyte. Veracyte's average media sentiment score of 1.29 beat Exelixis' score of 1.18 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	11 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veracyte has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

Exelixis has higher revenue and earnings than Veracyte. Exelixis is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	6.58	$66.35M	$1.41	30.01
Exelixis	$2.32B	5.78	$782.57M	$3.18	17.01

Summary

Exelixis beats Veracyte on 9 of the 16 factors compared between the two stocks.

How does Veracyte compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

BioMarin Pharmaceutical currently has a consensus price target of $88.83, indicating a potential upside of 33.17%. Veracyte has a consensus price target of $54.33, indicating a potential upside of 28.42%. Given BioMarin Pharmaceutical's higher possible upside, equities analysts plainly believe BioMarin Pharmaceutical is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

BioMarin Pharmaceutical has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	4.01	$348.90M	$0.37	180.27
Veracyte	$517.15M	6.58	$66.35M	$1.41	30.01

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 1.6% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Veracyte has a net margin of 20.37% compared to BioMarin Pharmaceutical's net margin of 2.14%. Veracyte's return on equity of 9.26% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Veracyte	20.37%	9.26%	8.61%

In the previous week, BioMarin Pharmaceutical had 24 more articles in the media than Veracyte. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 10 mentions for Veracyte. Veracyte's average media sentiment score of 1.29 beat BioMarin Pharmaceutical's score of 0.73 indicating that Veracyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	13 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market.

Summary

Veracyte beats BioMarin Pharmaceutical on 9 of the 16 factors compared between the two stocks.

How does Veracyte compare to Arrowhead Pharmaceuticals?

Veracyte (NASDAQ:VCYT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Veracyte currently has a consensus target price of $54.33, indicating a potential upside of 28.42%. Arrowhead Pharmaceuticals has a consensus target price of $97.33, indicating a potential upside of 11.74%. Given Veracyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Veracyte is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Veracyte has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	6.58	$66.35M	$1.41	30.01
Arrowhead Pharmaceuticals	$829.45M	14.79	-$1.63M	-$2.25	N/A

In the previous week, Arrowhead Pharmaceuticals had 5 more articles in the media than Veracyte. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 10 mentions for Veracyte. Veracyte's average media sentiment score of 1.29 beat Arrowhead Pharmaceuticals' score of 0.90 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veracyte has a net margin of 20.37% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Veracyte's return on equity of 9.26% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

Veracyte has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 1.6% of Veracyte shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Veracyte beats Arrowhead Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Veracyte compare to Halozyme Therapeutics?

Veracyte (NASDAQ:VCYT) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

97.8% of Halozyme Therapeutics shares are held by institutional investors. 1.6% of Veracyte shares are held by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Halozyme Therapeutics has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	6.58	$66.35M	$1.41	30.01
Halozyme Therapeutics	$1.66B	7.38	$316.89M	$3.35	32.29

In the previous week, Halozyme Therapeutics had 5 more articles in the media than Veracyte. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 10 mentions for Veracyte. Veracyte's average media sentiment score of 1.29 beat Halozyme Therapeutics' score of 1.04 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veracyte has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Veracyte presently has a consensus price target of $54.33, indicating a potential upside of 28.42%. Halozyme Therapeutics has a consensus price target of $91.20, indicating a potential downside of 15.69%. Given Veracyte's stronger consensus rating and higher possible upside, research analysts clearly believe Veracyte is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Halozyme Therapeutics has a net margin of 24.86% compared to Veracyte's net margin of 20.37%. Halozyme Therapeutics' return on equity of 260.98% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Summary

Halozyme Therapeutics beats Veracyte on 12 of the 17 factors compared between the two stocks.

Get Veracyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCYT vs. The Competition

Export

Metric	Veracyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.40B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	30.01	11.62	272.60	24.25
Price / Sales	6.58	1,338.17	618.96	99.78
Price / Cash	28.41	105.14	78.62	53.99
Price / Book	2.45	16.80	13.05	6.20
Net Income	$66.35M	-$12.50M	$3.47B	$348.59M
7 Day Performance	2.57%	3.29%	2.09%	0.08%
1 Month Performance	-26.90%	8.23%	6.64%	3.88%
1 Year Performance	36.48%	55.05%	25.02%	16.98%

Veracyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCYT Veracyte	4.3764 of 5 stars	$42.31 +1.2%	$54.33 +28.4%	+36.5%	$3.40B	$517.15M	30.01	790	News Coverage Positive News
TWST Twist Bioscience	1.5164 of 5 stars	$124.88 +8.0%	$98.30 -21.3%	+409.2%	$7.25B	$376.57M	N/A	990
EXEL Exelixis	3.3853 of 5 stars	$52.96 -2.1%	$49.79 -6.0%	+40.0%	$13.59B	$2.32B	16.65	1,077	News Coverage Positive News Analyst Forecast
BMRN BioMarin Pharmaceutical	4.8149 of 5 stars	$68.88 +7.9%	$88.00 +27.8%	+13.9%	$12.35B	$3.22B	186.16	3,221	Analyst Forecast High Trading Volume
ARWR Arrowhead Pharmaceuticals	2.2395 of 5 stars	$88.33 +0.8%	$97.33 +10.2%	+308.4%	$12.35B	$829.45M	N/A	400	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCYT) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veracyte (VCYT) Competitors

VCYT vs. TWST, EXEL, BMRN, ARWR, and HALO

How does Veracyte compare to Twist Bioscience?

Summary

How does Veracyte compare to Exelixis?

Summary

How does Veracyte compare to BioMarin Pharmaceutical?

Summary

How does Veracyte compare to Arrowhead Pharmaceuticals?

Summary

How does Veracyte compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT vs. The Competition

Veracyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veracyte (VCYT) Competitors

VCYT vs. TWST, EXEL, BMRN, ARWR, and HALO

How does Veracyte compare to Twist Bioscience?

Which has better valuation & earnings, VCYT or TWST?

Do analysts rate VCYT or TWST?

Is VCYT or TWST more profitable?

Which has more volatility & risk, VCYT or TWST?

Does the media prefer VCYT or TWST?

Summary

How does Veracyte compare to Exelixis?

Do institutionals & insiders hold more shares of VCYT or EXEL?

Do analysts rate VCYT or EXEL?

Is VCYT or EXEL more profitable?

Does the media refer more to VCYT or EXEL?

Which has more risk & volatility, VCYT or EXEL?

Which has stronger valuation & earnings, VCYT or EXEL?

Summary

How does Veracyte compare to BioMarin Pharmaceutical?

Do analysts recommend BMRN or VCYT?

Which has higher valuation & earnings, BMRN or VCYT?

Do insiders and institutionals believe in BMRN or VCYT?

Is BMRN or VCYT more profitable?

Does the media prefer BMRN or VCYT?

Which has more risk and volatility, BMRN or VCYT?

Summary

How does Veracyte compare to Arrowhead Pharmaceuticals?

Do analysts prefer VCYT or ARWR?

Which has higher valuation and earnings, VCYT or ARWR?

Does the media refer more to VCYT or ARWR?

Is VCYT or ARWR more profitable?

Which has more risk and volatility, VCYT or ARWR?

Do institutionals & insiders believe in VCYT or ARWR?

Summary

How does Veracyte compare to Halozyme Therapeutics?

Do institutionals and insiders hold more shares of VCYT or HALO?

Which has higher valuation and earnings, VCYT or HALO?

Does the media favor VCYT or HALO?

Which has more risk & volatility, VCYT or HALO?

Do analysts prefer VCYT or HALO?

Is VCYT or HALO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT vs. The Competition

Veracyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools